<DOC>
	<DOCNO>NCT01854606</DOCNO>
	<brief_summary>Study safety efficacy AEB071 EVEROLIMUS patient CD79-mutant ABC subtype Diffuse Large B-Cell Lymphoma . The trial progress Phase II due suboptimal tolerability combination treatment sotrastaurin everolimus Phase Ib part study . There serious safety concern associate combination .</brief_summary>
	<brief_title>Safety Efficacy AEB071 EVEROLIMUS Patients With CD79-mutant ABC Subtype Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This Phase Ib dose escalation Phase II study patient DLBCL harbor mutation CD79A/B ABC subtype . Pre-screening mutation CD79A/B ABC subtype require , anticipated patient group may receive clinical benefit combination AEB071 EVEROLIMUS .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female ≥18 year age . Diffuse DLBCL activate mutation CD79 ( A B subunit ) ABCsubtype DLBCL ( CD79 wildtype CD79 mutant ) . DLBCL arise transformed indolent lymphoma allow . Prior treatment relapse follow chemotherapy autologous bone marrow stem cell transplant . Patients transplant eligible respond chemotherapy may consider study follow single regimen chemotherapy RCHOP REPOCH . There limit number prior therapy allow . May treat localized radiation long measurable evaluable disease remain untreated site . WHO performance status ≤ 2 . A representative FFPE tumor sample must available molecular test along correspond pathology report . An archival tumor sample may submit . However , available , new tumor biopsy obtain purpose study must submit instead . Treatment strong inducer inhibitor ( medication herbal supplement ) cytochrome P450 3A4/5 ( CYP3A4/5 ) , CYP3A4/5 substrates QT prolongation risk discontinue least 7 halflives ( halflife unknown,14 day ) prior study drug treatment . Impaired cardiac function clinically significant cardiac disease . Impairment GI function GI disease could interfere absorption AEB071 everolimus . Severe systemic infection , current within two week prior initiation AEB071 . Kown history HIV . Poorly control diabetes define fast serum glucose &gt; 2.0 x ULN . Evidence current CNS involvement . Significant symptomatic deterioration lung function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma , DBCL , AEB071 , Everolimus</keyword>
</DOC>